Table 1
Data on 33 patients at time of the first electrochemotherapy
| Metastasis localization | N. of patients (%) |
|---|---|
| Loco-regional - exclusively | 12 (36.3) |
| Loco-regional + distal | 21 (63.6) |
| Distant metastasis | |
| 1 organ affected | 15 (45.4) |
| 2 organs affected | 3 (9) |
| > 2 organs affected | 3 (9) |
| Distant metastasis and organs affected | |
| Metastases → pulmonary/pleural | 11 (33) |
| Metastases → bone | 10 (30.3) |
| Metastases → cerebral | 3 (9) |
| Metastases → hepatic | 3 (9) |
Table 2
Systemic therapy at the time of electrochemotherapy
| Monochemotherapy | N. of patients |
|---|---|
| Eribulin | 8 |
| Taxane | 4 |
| Vinorelbine | 3 |
| Capecitabine | 3 |
| Mitomycin | 1 |
| Pegylated liposomal doxorubicin | 1 |
| Combo-chemotherapy | |
| Carboplatin & gemcitabine | 3 |
| Vinorelbine & capecitabine | 1 |
| Antibody therapy | |
| Trastuzumab | 6 |
| Bevacizumab | 4 |
| Endocrine monotherapy | |
| AI with everolimus & fulvestrant | 5 |
Table 3
Findings of locoregional recidivism prior to electrochemotherapy
| Areas of treated thorax wall | N. of patients (%) |
|---|---|
| On one side | 23 (69.7) |
| On two sides | 7 (21.2) |
| + axilla | 5 |
| + upper arm | 3 |
| + dorsal | 5 |
| + supra/infraclavicular | 1 |
Figure 1
Patient with triple negative breast cancer under chemotherapy before ECT. The patient was previously under treatment with taxanes, carboplatin and eribulin. In contrast to response in liver and lung metastasis, skin metastasis showed progression.
Figure 2
Two month after ECT. Good tumour control in the pretreated area was obtained but progression in the border is visible and partially with tumour-free area. Typical hyperpigmentation following ECT treatment is visible.
Table 4
Findings on patient characterization at initial diagnosis and after systemic therapy
| N. of patients (%) | N. of patients (%) | N. of patients (%) | |
|---|---|---|---|
| Tumour stage | pT1 | pT2 | pT3/4 |
| Total 18 patients | 7 (38.9) | 7 (38.9) | 4 (22.2) |
| Post-PST | ypT1 | ypT2 | ypT3/4 |
| Total of 15 patients | 2 (13.3) | 8 (53.3) | 5 (33.3) |
| Nodal stage | pNo | pN1 | pN2/3 |
| Total of 22 patients | 8 (36.3) | 6 (27.2) | 8 (36.3) |
| Post-PST | Nodal stage not determined | ypN2/3 | |
| Total of 11 patients | 4 (36.3) | 7 (63.6) |
[i] PST = primary systemic therapy